La cadena de opciones muestra datos clave de las opciones de acciones de Tonix Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Tonix Pharmaceuticals..

Tonix Pharmaceuticals (NASDAQ:TNXP) Bolsa, Cadena de Opciones

Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEON

ANIP

BBAI

BLRX

CFFI

DOYU

GCTK

LUXH

PMAX

QUBT

RIME

SANG

SIBN

SLXN

SOBR

SONM

TNXP

WHLR

TSMC y otras acciones destacaron en el premercado tras reportar ganancias récord. Descubre los mayores ganadores y perdedores.

Acciones de Taiwan Semiconductor (TSM) suben alrededor del 5%; 20 acciones en movimiento en el premercado de EE.UU.

Earnings

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company) presented data in a poster presentation at the Annual European Congress of Rheumatology (EULAR) 2025, held June 11-14, 2025, in Barcelona, Spain. A copy of the Company's poster, titled "Advancing Fibromyalgia Treatment: Transmucosal Sublingual Cyclobenzaprine (TNX-102 SL) Targets Non-restorative Sleep and Provides Sustained Pain Reduction" is available under the <a href="https://www.globenewswire.com/Tracker?data=MBp6l1yE0UYuANFRaHcakT0YpPLwFdMkVv-sG5Z_BvnjCtvkoXNw7HPbhK1-zdW4JM1EJ2PYcf93TvQj_jWARwKm4AcWfMIGm6k0D9E8TBDogMAvA-Ed6lx7yGcevp8aCLRndB_H7jzMldmlI6vXVA==">Scientific Presentations</a> tab of the Tonix website at <a href="https://www.globenewswire.com/Tracker?data=mGj3zEWAkLkG6yt-vdOMKrNKcn4d98neV0wPM7Qwclwxuv_s5u9qn_RLBKTfU7dN12xCDJuWSLwAyNgezDAcmKLcaKhduNktLFfrz5YzCqE=">www.tonixpharma.com</a>. TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is a non-opioid analgesic designed for daily bedtime dosing with an FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025.

Tonix Showcases New Fibromyalgia Drug That Targets Sleep and Pain Without Opioids

<a href="https://docs.publicnow.com/viewDoc?hash_primary=E1CE3DFED04FF79443CAC8D649FD1A421CF32415" title="https://docs.publicnow.com/viewDoc?hash_primary=E1CE3DFED04FF79443CAC8D649FD1A421CF32415">https://docs.publicnow.com/viewDoc?hash_primary=E1CE3DFED04FF79443CAC8D649FD1A421CF32415</a>

Biotech

General

Tonix Pharmaceuticals Releases June 2025 Virtual Investor Presenation, Shares Key Updates On Pipeline And Strategic Initiatives

Tonix Pharmaceuticals Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) saw its shares decline Thursday morning after the company <a href="https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-25-007635/0001999371-25-007635.pdf">filed</a> a Form S-3 with the U.S. Securities and Exchange Commission.
What To Know: The filing registers the company to offer and sell up to $500 million of various securities. The &#8220;shelf&#8221; registration allows Tonix to sell common stock, preferred stock, warrants, debt securities and other units from time to time. The company <a href="https://ir.tonixpharma.com/sec-filings/all-sec-filings/content/0001999371-25-007635/0001999371-25-007635.pdf">stated</a> it intends to use any net proceeds for working capital and general corporate purposes.
Tonix is a biotechnology company focused on central nervous system disorders. Its priority is advancing TNX-102 SL for fibromyalgia management, which has a PDUFA goal date of August 15, for a marketing authorization decision from the FDA.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TNXP stock is trading lower by approximately 11.8% at $33.26 Thursday morning. The stock has a short interest of 14.42% of its float, indicating a notable level of bearish sentiment.
Read Also: <a href="https://www.benzinga.com/markets/economic-data/25/06/45902987/producer-inflation-rises-less-than-forecasts-in-may-jobless-claims-signal-labor-market-cracks">Producer Inflation Rises Less Than Forecasts In May, Jobless Claims Signal Labor Market Cracks</a>
<h2 class="wp-block-heading">How To Buy TNXP Stock</h2>
By now you're likely curious about how to participate in the market for Tonix Pharmaceuticals &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Tonix Pharmaceuticals, which is trading at $33.48 as of publishing time, $100 would buy you 2.99 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from Benzinga Pro, TNXP has a 52-week high of $137.25 and a 52-week low of $6.76.
Image: Shutterstock

Tonix Pharmaceuticals (TNXP) Files To Raise $500 Million, Shares Tumble

WIIM

Tonix Pharmaceuticals shares are trading lower after the company filed for a $500 million shelf offering.

We may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, warrants, senior or subordinated debt securities, subscription rights or units having an aggregate initial offering price not exceeding $500,000,000. The debt securities may consist of debentures, notes, or other types of debt. The preferred stock, warrants, debt securities, subscription rights and units may be convertible or exercisable or exchangeable for common stock or preferred stock or other securities of ours and have not been approved for listing on any market or exchange, and we have not made any application for such listing. The units may consist of any combination of the securities listed above.

Offerings

Reported Earlier: Tonix Pharmaceuticals Files For $500M Shelf Offering

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Thursday.
Shares of Oxford Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) fell sharply in today's pre-market trading as the company reported in-line earnings for the first quarter and issued second-quarter earnings guidance below estimates. Also, the company <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45877826/oxford-industries-likely-to-report-lower-q1-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">lowered its FY25 guidance.</a>
Oxford Industries posted adjusted EPS of $1.82, in-line with estimates. The company's quarterly sales came in at $392.86 million versus expectations of $384.77 million.
Oxford Industries shares dipped 10.1% to $44.99 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) dipped 17% to $31.32 in pre-market trading. Tonix Pharmaceuticals may sell up to $150 million in common stock.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) fell 12.4% to $24.97 in pre-market trading after the company announced a $1.75 billion proposed private offering of convertible senior notes.</li>
<li>Karooooo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KARO#NASDAQ">KARO</a>) dipped 11.1% to $52.94 in pre-market trading.</li>
<li>Yiren Digital Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) declined 10.1% to $6.69 in pre-market trading.</li>
<li>QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) fell 9.9% to $10.87 in pre-market trading.</li>
<li>DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) dipped 8.6% to $24.00 in pre-market trading.</li>
<li>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) fell 7.4% to $198.10 in pre-market trading. An Air India Boeing 787-8 Dreamliner by Boeing crashed on Thursday near the India's Ahmedabad airport, with 242 passengers on board. The flight was en route to London Gatwick from Ahmedabad.</li>
<li>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) fell 4.4% to $234.57 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a> </li>
</ul>
Photo via Shutterstock

DFDV

KARO

Oxford Industries, GameStop, Boeing And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 115.2% to $0.02 during Thursday's pre-market session. The company's market cap stands at $8.0 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock rose 31.32% to $14.59. The market value of their outstanding shares is at $379.5 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock moved upwards by 19.31% to $1.73. The company's market cap stands at $56.2 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares rose 15.15% to $2.28. The market value of their outstanding shares is at $2.3 million. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) stock moved upwards by 14.78% to $1.63. The market value of their outstanding shares is at $117.1 million. </li>
<li>TherapeuticsMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXMD#NASDAQ">TXMD</a>) stock rose 11.66% to $1.34. The company's market cap stands at $15.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares decreased by 48.7% to $0.3 during Thursday's pre-market session. The market value of their outstanding shares is at $5.4 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock decreased by 39.93% to $0.67. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock decreased by 26.68% to $0.44. The market value of their outstanding shares is at $4.8 million. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) shares decreased by 22.62% to $1.54. The market value of their outstanding shares is at $50.9 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock declined by 22.28% to $29.31. The company's market cap stands at $214.6 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares decreased by 13.83% to $0.32. The company's market cap stands at $1.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HCTI

HSDT

INTS

JUNS

KLTO

LIMN

NUWE

TXMD

VTAK

WGRX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Shares of Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued upbeat <a href="https://www.benzinga.com/quote/ORCL">outlook commentary</a>.
The company reported fourth-quarter revenue of $15.9 billion, beating analyst estimates of $15.58 billion. The company reported fourth-quarter adjusted earnings of $1.70 per share, beating analyst estimates of $1.64 per share, according to Benzinga Pro.
Oracle shares jumped 7.6% to $189.99 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) surged 141.3% to $0.0222 in pre-market trading after gaining 28% on Wednesday.</li>
<li>Greenlane Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares jumped 78% to $0.0137 in pre-market trading after adding 8% on Wednesday.</li>
<li>Creative Global Technology Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTL#NASDAQ">CGTL</a>) jumped 73.4% to $1.60 in pre-market trading.</li>
<li>Graphjet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) gained 26.6% to $0.0814 in pre-market trading. Graphjet Technology, on June 11, submitted appeal to the Nasdaq Requesting hearing before Hearings Panel.</li>
<li>Zhongchao Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) climbed 24.1% to $1.29 in pre-market trading after dipping 22% on Wednesday.</li>
<li>Houston American Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) rose 22.2% to $6.65 in pre-market trading after jumping 24% on Wednesday.</li>
<li>Liminatus Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) rose 21.8% to $13.53 in pre-market trading after dipping 50% on Wednesday.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) surged 14.7% to $18.70 in pre-market trading after the company announced the first volume shipment of data center transceivers to a hyperscale customer.</li>
<li>Solid Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) gained 13.4% to $2.12 in pre-market trading after jumping 15% on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Intensity Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares tumbled 47.7% to $0.3020 in pre-market trading after the company announced a proposed public offering.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) dipped 42.5% to $0.6397 in pre-market trading. Helius Medical Technologies shares gained 31% on Wednesday after the company announced an authorized claim for payment for the PoNS Device from Aetna Healthcare.</li>
<li>Catheter Precision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NASDAQ">VTAK</a>) shares fell 30.2% to $0.4223 in pre-market trading after jumping 165% on Wednesday.</li>
<li>Jupiter Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) declined 19.6% to $1.60 in pre-market trading after jumping 106% on Wednesday.</li>
<li>Hycroft Mining Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYMC#NASDAQ">HYMC</a>) declined 19.5% to $3.43 in pre-market trading after the company announced a $40 million public offering of units.</li>
<li>Distoken Acquisition Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIST#NASDAQ">DIST</a>) fell 18.8% to $16.00 in pre-market trading after jumping 64% on Wednesday.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) dipped 17% to $31.32 in pre-market trading. Tonix Pharmaceuticals may sell up to $150 million in common stock.</li>
<li>707 Cayman Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JEM#NASDAQ">JEM</a>) declined 17% to $5.76 in pre-market trading after jumping 73% on Wednesday.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) fell 12.4% to $24.97 in pre-market trading after the company announced a $1.75 billion proposed private offering of convertible senior notes.</li>
<li>Oxford Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) fell 10.1% to $44.99 in pre-market trading. Oxford Industries reported in-line earnings for the first quarter and issued second-quarter earnings guidance below estimates.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a> </li>
</ul>
Photo via Shutterstock

AAOI

CGTL

DIST

GNLN

HUSA

Hycroft Mining Holding Corporation - Class A Common Stock

HYMC

ORCL

SLDP

ZCMD

Why Oracle Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Tonix Pharmaceuticals May Sell Up To $150M In Common Stock; Enters $75M Purchase Agreement With Lincoln Park

https://www.who.int/news/item/09-06-2025-fourth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-upsurge-of-mpox-2024-temporary-recommendations

AEMD

GOVX

MRNA

VRAX

World Health Organization Says MPOX Remains A Public Health Emergency Of International Concern

Tonix Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares have nearly doubled over the past month despite the pullback on Wednesday. Here&#8217;s what you <a href="https://www.benzinga.com//node/45469232">need to know.</a>
What To Know: Tonix shares traded higher in early May after the company reported first-quarter earnings and CEO Seth Lederman disclosed he bought 4,000 shares of the company&#8217;s stock for $86,200.
In the latest earnings report, Tonix posted a loss of $2.48 per share, beating the consensus estimate for a loss of $3.37 per share. Revenue came in at $2.43 million, slightly below estimates of $2.55 million.
The company ended the quarter with $131.7 million in cash and cash equivalents and said it had sufficient funds to support operations through the second quarter.
Tonix also provided updates on its pipeline, highlighting that TNX-102 SL (cyclobenzaprine HCl sublingual tablets) remains on track as a potential treatment for fibromyalgia. The company is exploring its use across several other conditions as well.
See Also: <a href="https://www.benzinga.com/25/05/45649139/arrived-debuts-seattle-focused-fund-as-tech-hubs-housing-market-regains-momentum">Arrived Debuts Seattle-Focused Fund As Tech Hub&#8217;s Housing Market Regains Momentum</a>
Last week, Tonix announced that the first patient had been dosed in its Phase 2 OASIS study of TNX-102 SL for the treatment of Acute Stress Reaction (ASR).
"TNX-102 SL has been shown to improve sleep quality in PTSD, and previous trials suggest benefits for stress-related symptoms early in treatment," Lederman said.
"Addressing sleep disturbances is key to managing ASR, as poor sleep can worsen other symptoms and delay recovery."
Tonix Pharmaceuticals shares are seeing increased attention in recent weeks as the stock has been trending across various social platforms. The stock appears to be pulling back Wednesday following the recent rally. 
TNXP Price Action: At the time of publication, <a href="http://benzinga.com/quote/tnxp">Tonix shares</a> were down 2.65% at $36.01, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjg1tDoysaNAxXPGVkFHc0oE9wQFnoECAwQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro.</a> The stock is up approximately 99% over the past month and has climbed more than 325% over a three-month period.
Image: Shutterstock.

What's Going On With Tonix Pharmaceuticals Stock?

<h3>Gainers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares rose 60.0% to $0.64 during Tuesday's regular session. The market value of their outstanding shares is at $2.3 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) stock rose 40.28% to $11.91. The market value of their outstanding shares is at $78.4 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock rose 29.08% to $37.34. The company's market cap stands at $273.5 million. </li>
<li>Anteris Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVR#NASDAQ">AVR</a>) stock increased by 27.19% to $4.63. The company's market cap stands at $166.4 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares moved upwards by 24.24% to $0.93. The company's market cap stands at $111.5 million. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) shares rose 24.05% to $2.63. The market value of their outstanding shares is at $90.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) shares decreased by 61.9% to $2.39 during Tuesday's regular session. The company's market cap stands at $257.2 million. </li>
<li>NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) shares declined by 34.0% to $11.67. The company's market cap stands at $382.7 million. </li>
<li>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) stock fell 30.95% to $4.54. The company's market cap stands at $244.5 million. </li>
<li>Savara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRA#NASDAQ">SVRA</a>) stock decreased by 30.64% to $1.97. The market value of their outstanding shares is at $340.4 million. </li>
<li>EXoZymes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXOZ#NASDAQ">EXOZ</a>) shares declined by 26.31% to $10.98. The market value of their outstanding shares is at $91.8 million. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) stock fell 20.01% to $0.98. The market value of their outstanding shares is at $130.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXOZ

FBRX

IVVD

NOTV

NPCE

PRTA

RAPT

RCKT

SVRA

WORX

12 Health Care Stocks Moving In Tuesday's Intraday Session

Investigator-initiated Phase 2 trial to evaluate TNX-102 SL's potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD)
Trial is sponsored by the University of North Carolina (UNC) and supported by a grant from the U.S. Department of Defense
Topline results from the trial are expected in the second half of 2026
CHATHAM, N.J., May 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced the first patient has been dosed in the Phase 2, investigator-initiated OASIS trial to evaluate TNX-102 SL in reducing the severity of acute stress reaction (ASR) and the frequency of acute stress disorder (ASD). The trial is sponsored by the University of North Carolina (UNC) Institute for Trauma Recovery and supported by a $3 million grant from the U.S. Department of Defense (DoD).
The Optimizing Acute Stress Reaction Interventions with TNX-102 SL (OASIS) trial will examine the safety and efficacy of TNX-102 SL to reduce adverse posttraumatic neuropsychiatric sequelae among patients presenting to the emergency department (ED) after a motor vehicle collision (MVC). The trial plans to enroll approximately 180 MVC-trauma survivors at ED study sites around the U.S. Participants will be randomized in the ED to receive a two-week course of either TNX-102 SL 5.6 mg or placebo.
The OASIS trial will build upon a foundation of knowledge and infrastructure developed through the UNC-led, $40 million AURORA initiative. AURORA is a major national research initiative to improve the understanding, prevention and recovery of individuals who experience a traumatic event. AURORA is supported by funding from the National Institutes of Health (NIH), leading brain health nonprofit One Mind, private foundations, and partnerships with leading tech companies, such as Mindstrong Health and Verily Life Sciences, the healthcare arm of Alphabet, the parent company of Google.
Acute and chronic stress disorders can affect both civilian and military populations. According to the National Center for PTSD, in the U.S. about 60% of men and 50% of women experience at least one trauma in their lives In the U.S. alone, one-third of ED visits (40-50 million patients per year) involve evaluation after trauma exposures, and in a 2014 study involving 3,157 US veterans, 87% reported exposure to at least one potentially traumatic event during their service. Moreover, as many as 500,000 U.S. troops who served in wars between 2001 and 2015 were diagnosed with PTSD. Currently, no medication is available in the immediate aftermath of traumatic events to treat the initial reaction and support long term health via a post-trauma clinical trajectory that prevents development or worsening of ASD, thereby also preventing PTSD.

Tonix Pharma Announces First Patient Dosed In Phase 2, Investigator-Initiated OASIS Trial To Evaluate TNX-102 SL In Reducing Severity Of ASR And Frequency Of ASD

Tonix Pharmaceuticals Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares are trading higher by 13.2% to $26.14 on Friday, continuing a strong week with a 33.5% gain fueled by encouraging first-quarter developments.
Investor sentiment was also boosted Thursday after CEO Seth Lederman <a href="https://www.benzinga.com/quote/TNXP/insider-trades">disclosed</a> the purchase of 4,000 shares of company stock for $86,200.
What To Know: Tonix on Monday <a href="https://www.benzinga.com/pressreleases/25/05/g45360480/tonix-pharmaceuticals-reports-first-quarter-2025-financial-results-and-operational-highlights">reported</a> a first-quarter loss of $2.84 per share, beating analyst estimates of a $3.37 loss. Revenue came in slightly below expectations at $2.43 million versus $2.55 million consensus.
The company continues to advance its lead drug candidate, TNX-102 SL, for fibromyalgia. The drug has a PDUFA decision date set for August 15, and if approved, could become the first new FDA-approved fibromyalgia treatment in over 15 years.
Read Also: <a href="https://www.benzinga.com/25/05/45418446/this-weeks-best-short-squeeze-options-trade">This Week&#8217;s Best Short Squeeze Options Trade</a>
The company noted that no FDA advisory committee meeting is required, which typically signals a smoother regulatory path.
Tonix also <a href="https://www.benzinga.com/pressreleases/25/05/g45360480/tonix-pharmaceuticals-reports-first-quarter-2025-financial-results-and-operational-highlights">highlighted</a> pipeline progress, including positive Phase 1 results for TNX-1500 (organ transplant rejection) and preclinical data for TNX-801 (smallpox and mpox vaccine). 
Financially, the company ended the first quarter with $131.7 million in cash, strengthened by recent equity raises and a share repurchase of 150,000 shares.
Read Also: <a href="https://www.benzinga.com/25/05/45466937/us-targets-european-digital-rules-in-free-speech-campaign-defending-american-big-tech">US Slams Europe&#8217;s Digital Laws, Calls Them A Danger To Free Expression And American Big Tech</a>
<h2 class="wp-block-heading">How To Buy TNXP Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Tonix Pharmaceuticals&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TNXP has a 52-week high of $672.00 and a 52-week low of $6.76.

Tonix Pharmaceuticals (TNXP) Stock Surges Following Insider Buying And Q1 Results

<h3>Gainers</h3>
<ul>
<li>Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) shares moved upwards by 176.1% to $3.92 during Friday's pre-market session. The market value of their outstanding shares is at $251.8 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock increased by 28.78% to $0.25. The company's market cap stands at $7.2 million. The company's, Q1 earnings came out yesterday. </li>
<li>Kalaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLRS#NASDAQ">KLRS</a>) stock increased by 21.46% to $4.3. The market value of their outstanding shares is at $80.4 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) stock moved upwards by 13.81% to $2.06. The company's market cap stands at $104.5 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock increased by 12.34% to $6.17. The company's market cap stands at $334.7 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock increased by 11.55% to $25.77. The market value of their outstanding shares is at $165.8 million. As per the news, the Q1 earnings report came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock fell 65.7% to $0.01 during Friday's pre-market session. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares declined by 19.53% to $47.04. The market value of their outstanding shares is at $8.7 billion. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) stock declined by 17.26% to $17.5. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) stock declined by 13.85% to $2.23. The market value of their outstanding shares is at $13.7 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock decreased by 13.08% to $0.3. The market value of their outstanding shares is at $7.6 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares decreased by 12.0% to $3.52. The market value of their outstanding shares is at $6.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AYTU

CABA

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DOCS

INZY

KLRS

SNSE

TVTX

12 Health Care Stocks Moving In Friday's Pre-Market Session

Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) reported quarterly losses of $(2.84) per share which beat the analyst consensus estimate of $(3.37) by 15.73 percent. This is a 99.51 percent increase over losses of $(576.00) per share from the same period last year. The company reported quarterly sales of $2.43 million which missed the analyst consensus estimate of $2.55 million by 4.75 percent. This is a 2.14 percent decrease over sales of $2.48 million the same period last year.

Earnings Beats

Earnings Misses

Tonix Pharmaceuticals Q1 EPS $(2.84) Beats $(3.37) Estimate, Sales $2.43M Miss $2.55M Estimate

Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells
TNX-1700 is in preclinical development for gastric and colorectal cancers

Events

Tonix Pharmaceuticals Presented Preclinical Data On Gastric Cancer Models At AACR 2025 Annual Meeting

Tonix Pharmaceuticals Discontinued Enrollment And Terminated Phase 2 Catalyst Study Of Its TNX-1300 Product; The Company Is Evaluating New Study Designs And New Endpoints For Further Development Of TNX-1300

Agreement includes the use of Tonix's TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana's genetically engineered pig organs in xenotransplantation.
 &nbsp;

Tonix Pharmaceuticals And Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) With Makana's Genetically Engineered Organs In Preclinical And Clinical Xenotransplantation Studies

<ul>
<li>TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia</li>
<li>TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two pivotal double-blind randomized Phase 3 studies</li>
<li>FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia</li>
<li>If approved by FDA, it would become the first member of a new class of non-opioid analgesic drugs for fibromyalgia and the first new drug for treating fibromyalgia in more than 15 years</li>
</ul>

Health Care

Tonix Pharmaceuticals Presented Data And Analyses Of TNX-102 SL Treatment Effects On Fibromyalgia At The American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Press Releases

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights

Management

Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase

Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025

Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention

Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James "Jim" Hunter, to Board of Directors

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Altimmune

Annexon

Candel Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Citius Oncology

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Foghorn Therapeutics

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

Immutep Limited - American Depositary Shares

Immutep

Inozyme Pharma

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Nanobiotix

Neurogene

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Tevogen Bio Holdings

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Verastem

Noble Capital Markets

Alliance Global Partners

Dawson James

Untitled design - 2025-03-31T165341.547

VRTX

Tonix&#39;s Experimental Non-Opioid Analgesic Treatment For Fibromyalgia Could Start Bringing Relief Later This Year

Screenshot 2025-03-19 at 8.55.22 PM

BVNKF

As Mpox Cases Spread Around The World, Tonix Pharmaceuticals&#39; Single-Dose Vaccine TNX-801 Has Potential To Slow The Spread

Screenshot 2025-03-12 at 4.47.01 PM

Tonix&#39;s TNX-1500 Shows Promise In Preventing Organ Transplant Rejections Of Either Human Or Pig Organs; Autoimmune Diseases Also A Target

Comments

Tonix Pharmaceuticals

Tonix Pharmaceuticals (TNXP) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL